Corcept Therapeutics (CORT) Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steato
- Nasdaq, S&P 500 scale new peak as jobs recovery gains traction
- Biden says deal reached on infrastructure plan
- Eli Lilly (LLY) Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen (BIIB) Plunges
- Dollar holds below two-month highs as Fed policy in focus, sterling slips
- Morgan Stanley's Huberty Dismisses Concerns Over Apple's (AAPL) 2022 Growth Prospects, Bumps PT; Says iPhone 'S' Cycle Is Different This Time and Sees 'Good' LT Buying Opportunity
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced interim findings from the Phase 2 trial of its selective cortisol modulator miricorilant in patients with presumed NASH.
“This was our first trial to evaluate miricorilant as a treatment for patients with liver disease. When we observed elevated ALT and AST levels in four of the first five patients who received miricorilant for four weeks, we suspended the study,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. “Our investigation has made two notable findings. First, the elevations in ALT and AST resolved after miricorilant was withdrawn.” (See Figures 1 and 2)
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/00d4659c-26e2-4ecf-aa44-10cefb13a5d3
“Second, the patients with elevated liver enzymes exhibited large reductions in liver fat rapidly.” (See Table 1)
|Patient||Miricorilant (per day)||Days on Drug||% Liver Fat at Baseline||% Liver Fat at Follow up||Days Between Last Dose and Follow-up||RelativeReduction in % Liver Fat|
|Patient 1||900 mg||30||17.6||6.1||19||-65.3||%|
|Patient 2||900 mg||31||27.8||17.1||64||-38.5||%|
|Patient 3||900 mg||44||28.3||15.0||16||-47.0||%|
|Patient 4||600 mg||34||12.6||3.3||21||-73.8||%|
|Table 1: Reduction in liver fat content measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF)|
“We had planned to enroll 120 patients in this study, which we thought would be sufficient to detect a 30 percent reduction in liver fat after 12 weeks,” continued Dr. Grauer. “These patients exhibited much larger reductions after receiving miricorilant for 4-6 weeks. These findings are particularly striking because their follow-up liver MRI was some distance from their final dose.”
“Liver fat reductions achieved this quickly and of this magnitude are rarely seen ,” said Dr. Stephen A. Harrison, M.D., Medical Director for Pinnacle Clinical Research, San Antonio, Texas, Visiting Professor of Hepatology, Oxford University and principal investigator in Corcept’s Phase 2 trial. “Fatty liver disease and NASH afflict many millions of people and there are no approved treatments. Further study is warranted to evaluate if miricorilant can produce such significant reductions in liver fat safely and that the reduction results in a meaningful improvement in NASH.”
About the Phase 2 Trial
This double-blind, placebo-controlled Phase 2 study is designed to enroll 120 patients with presumed NASH at 15 clinical sites in the United States. Patients are randomized 1:1:1 to receive a daily dose of 600 mg of miricorilant, 900 mg of miricorilant or placebo. The trial’s primary endpoint is reduction in liver fat at week 12 as assessed by MRI-PDFF, with a secondary endpoint being the proportion of patients who exhibit liver fat reduction of at least 30 percent at week 12. Additional information about the study (NCT03823703) is at www.ClinicalTrials.gov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sorrento Therapeutics (SRNE) Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX
- Monopar Therapeutics (MNPR) to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
- VectivBio (VECT) Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!